These authors found that other factors, such as the presence of lymph node metastases, extrathyroidal invasion, or histologic type of PTC, provide higher accuracy in predicting disease outcome than BRAF mutation status alone [49,50,51]. The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.